Bristol-Myers Squibb (BMY) vs GSK (GSK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed GSK (GSK) over the past year, gaining 33.8% versus a gain of 7.4%. Over five years, GSK leads with a +19.3% price change compared with +2.1% for BMY. Bristol-Myers Squibb is the larger company by market cap ($121.72 billion vs $93.17 billion), about 1.3 times the size.
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (9.0x vs 9.4x for GSK). Bristol-Myers Squibb offers the higher dividend yield (4.21% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | GSK |
|---|---|---|
| Share price | $59.59 | $46.51 |
| Market cap | $121.72B | $93.17B |
| 1-day change | +0.01% | -0.08% |
| YTD return | +10.46% | -5.10% |
| 1-year return | +33.77% | +7.36% |
| 5-year return | +2.09% | +19.30% |
| P/E ratio (TTM) | 13.12 | 14.67 |
| Forward P/E | 9.02 | 9.41 |
| EPS (TTM) | $4.54 | $3.17 |
| Dividend yield | 4.21% | 1.46% |
| Annual dividend | $2.51 | $0.68 |
| Revenue (latest FY) | $48.19B | — |
| Revenue growth (YoY) | -0.22% | — |
| Net income (latest FY) | $7.05B | — |
| Gross margin | 71.08% | — |
| Net margin | 14.64% | — |
| 52-week high | $68.64 | $61.70 |
| 52-week low | $42.52 | $42.85 |
| Distance from 52-week high | -13.19% | -24.63% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +11.05% | +27.58% |
| Average volume | 11.30M | 3.85M |
| Shares outstanding | 2.04B | 2.00B |
| Employees | 32,500 | 66,841 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMY has outperformed GSK by 26.4 percentage points over the past year.
- Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.21% vs 1.46%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
BMY vs GSK FAQ
Which is bigger, Bristol-Myers Squibb or GSK?
Bristol-Myers Squibb (BMY) is larger, with a market capitalization of $121.72B compared with $93.17B for GSK (GSK).
Which stock has performed better over the past year, BMY or GSK?
BMY returned +33.77% over the past 12 months, compared with +7.36% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or GSK?
BMY has the lower trailing P/E at 13.1, versus 14.7 for GSK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or GSK?
Bristol-Myers Squibb has the higher yield at 4.21%, compared with 1.46% for GSK.
Are Bristol-Myers Squibb and GSK in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.